Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital

Plus Therapeutics (NASDAQ:PSTV) was downgraded by stock analysts at D Boral Capital from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Ascendiant Capital Markets lifted their price objective on shares of Plus Therapeutics from $19.00 to $20.00 and gave the company a “buy” rating in a report on Monday, April 21st. HC Wainwright dropped their price target on shares of Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating on the stock in a research report on Friday, March 28th. Finally, D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a report on Monday.

Plus Therapeutics Stock Performance

PSTV stock opened at $0.50 on Monday. The stock’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $1.10. The company has a market cap of $8.50 million, a P/E ratio of -0.20 and a beta of 0.88. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The firm had revenue of $1.80 million during the quarter, compared to the consensus estimate of $1.19 million. Equities analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.